BIOS Capital Management LP purchased a new stake in Actuate Therapeutics (NASDAQ:ACTU - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,893,651 shares of the company's stock, valued at approximately $78,753,000. Actuate Therapeutics makes up about 83.7% of BIOS Capital Management LP's portfolio, making the stock its largest holding. BIOS Capital Management LP owned approximately 50.66% of Actuate Therapeutics at the end of the most recent reporting period.
Separately, Freestone Capital Holdings LLC purchased a new stake in Actuate Therapeutics during the fourth quarter valued at about $80,000.
Actuate Therapeutics Stock Up 2.3%
Shares of ACTU stock traded up $0.23 during midday trading on Friday, reaching $10.33. 46,719 shares of the stock were exchanged, compared to its average volume of 48,059. Actuate Therapeutics has a 1 year low of $5.51 and a 1 year high of $11.73. The company's 50 day moving average is $8.53 and its two-hundred day moving average is $8.34.
Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.06).
Analysts Set New Price Targets
ACTU has been the subject of several research reports. Craig Hallum initiated coverage on Actuate Therapeutics in a research note on Tuesday, April 22nd. They issued a "buy" rating and a $21.00 target price for the company. HC Wainwright initiated coverage on shares of Actuate Therapeutics in a research report on Monday, March 17th. They issued a "buy" rating and a $20.00 target price on the stock.
Get Our Latest Research Report on ACTU
Actuate Therapeutics Profile
(
Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
See Also
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
